| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.TP.0000191940.13473.59 |
| P698 | PubMed publication ID | 16421481 |
| P50 | author | Stuart Knechtle | Q56958780 |
| P2093 | author name string | John H Fechner | |
| Huaizhong Hu | |||
| Debra D Bloom | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 81-87 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients | |
| P478 | volume | 81 |
| Q40270917 | Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients. |
| Q39513891 | Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness |
| Q36880514 | Alemtuzumab as compared to alternative contemporary induction regimens. |
| Q86254890 | Alemtuzumab induction and antibody-mediated rejection in kidney transplantation |
| Q46245992 | Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells |
| Q34409131 | Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review |
| Q36981652 | Allogeneic islet transplantation |
| Q38009874 | Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. |
| Q36229698 | Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation |
| Q36925946 | BAFF is increased in renal transplant patients following treatment with alemtuzumab |
| Q41767360 | CD28 blockade induces division-dependent downregulation of interleukin-2 receptor alpha |
| Q46569157 | Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. |
| Q36908763 | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol |
| Q36798362 | Current concepts and perspectives of immunosuppression in organ transplantation |
| Q37834028 | Current immunosuppressive treatment after kidney transplantation |
| Q37900647 | Current landscape for T-cell targeting in autoimmunity and transplantation |
| Q35038071 | Development of tolerogenic strategies in the clinic |
| Q53595595 | Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. |
| Q40916665 | Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. |
| Q96297762 | Immunosuppression-induced clonal T-cell lymphoproliferative disease causing severe diarrhoea mimicking coeliac disease following renal transplantation: a case report |
| Q36501667 | Is clinical tolerance realistic in the next decade? |
| Q35881889 | Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation |
| Q57121616 | Lymphocyte Depletion and Repopulation in Peripheral Blood and Small Intestine of Cynomolgus Monkeys After Alemtuzumab Treatment |
| Q53861449 | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. |
| Q37362699 | Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys |
| Q36769110 | Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients |
| Q35615865 | Rapid quantification of naive alloreactive T cells by TNF-alpha production and correlation with allograft rejection in mice |
| Q38187176 | Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy |
| Q36895544 | Renal transplantation in high-risk patients |
| Q39409394 | Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. |
| Q26774993 | The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients |
| Q51010023 | The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. |
| Q36570565 | The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation |
| Q38747419 | The immunological function of CD52 and its targeting in organ transplantation |
| Q37728218 | The response of intestinal stem cells and epithelium after alemtuzumab administration |
| Q33891696 | The role of B cells in solid organ transplantation. |
| Q37474964 | Translating costimulation blockade to the clinic: lessons learned from three pathways |
| Q33396236 | Use of monoclonal antibodies in renal transplantation |
| Q47209893 | Weight-based dosing of alemtuzumab: an ounce of prevention? |
Search more.